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Preface
This review of acute rheumatic fever and rheumatic heart disease 
among Indigenous Australians has been prepared by the Australian 
Indigenous HealthInfoNet as a part of our contributions to ‘closing 
the gap’ in health between Indigenous people and other Australians 
by making relevant, high quality knowledge and information easily 
accessible to policy makers, health service providers, program 
managers, clinicians, researchers and the general community.1 The 
review is an example of the HealthInfoNet’s translational research 
[2], defined as ‘comprehensive applied research that strives to 
translate the available knowledge and render it operational’ 
[3, p .1794].
The main purpose of the review, which follows the model of 
narrative reviews/syntheses [4], is to provide an authoritative, 
up-to-date review of acute rheumatic fever and rheumatic heart 
disease among Indigenous people that: (1) is a valuable overview 
for people working in the area; and (2) assists in the development/
refinement of policies, strategies and programs. 
Research for the review involved the collection, collation, and 
analysis of a wide range of relevant information, including both 
published and unpublished material. Sources include the full 
range of relevant literature, including journal articles and other 
1 The term Indigenous is used in this review to refer generally to the two 
Indigenous populations of Australia – Australian Aboriginal people and 
Torres Strait Islanders.
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relevant publications, the vast majority of which are accessible 
via the HealthInfoNet’s Australian Indigenous HealthBibliography. 
This bibliography, with more than more 20,000 entries, captures 
all relevant journal articles, books, book chapters and reports 
(including the ‘grey’ literature).
As well as the relevant journal literature, the HealthInfoNet’s reviews 
draw on important government reports, particularly those produced 
by the Australian Bureau of Statistics (ABS), the Australian Institute 
of Health and Welfare (AIHW) and the Steering Committee for the 
Review of Government Service Provision (SCRGSP), and reports 
in the Aboriginal and Torres Strait Islander health performance 
framework series. These reports, prepared by the Australian Health 
Ministers’ Advisory Council (AHMAC) in 2006, 2008, 2011 and 
2012, are accompanied by substantial detailed analyses, which are 
accessible on the AIHW website. The HealthInfoNet’s reviews also 
draw on information from the main administrative data collections 
(such as the birth and death registration systems and the hospital 
inpatient collections) and national surveys. Information from 
these sources has been published mainly in government reports, 
particularly those produced by the ABS and the AIHW.
After providing the context of acute rheumatic fever and rheumatic 
heart disease, the body of the review outlines the extent of acute 
rheumatic fever and rheumatic heart disease among Indigenous 
people, provides an overview of the various contributing factors, 
considers prevention and management, summarises a number of 
relevant policies and strategies, and provides some brief concluding 
comments. Rather than commence with an executive summary, 
the review is preceded by a section devoted to ‘Key facts’, which 
presents the summarised information in a more concise form.
Further information about acute rheumatic fever and rheumatic 
heart disease among Indigenous people is accessible from 
the relevant section of HealthInfoNet’s web resource (www.
healthinfonet.ecu.edu.au), which provides access to: the complete 
Indigenous-specific literature; details of policies and strategies, 
programs and projects, and organisations involved in the area; and 
databases of health promotion and health practice resources. The 
section also contains a plain language version of this review.
We welcome your comments and feedback about the review.
Neil Thomson, Director, on behalf of the HealthInfoNet team
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Key facts
Indigenous population
•	 At 30 June 2011, the estimated Australian Indigenous 
population was 669,736. 
•	 NSW had the highest number of Indigenous people (208,364, 
31% of the total Indigenous population); the NT had the 
highest proportion of Indigenous people in its population 
(30% of the NT population are Indigenous).
•	 In 2011, the majority of Indigenous people lived in cities and 
towns; around one quarter of Indigenous people lived in 
remote or very remote areas.
•	 The Indigenous population is much younger than the non-
Indigenous population.
Acute rheumatic fever
•	 Acute rheumatic fever (ARF) and new cases of rheumatic 
heart disease (RHD) are almost exclusively experienced by 
Indigenous people in Australia; Indigenous children and 
young adults are most affected by ARF and RHD.
•	 There were 317 notifications of new and recurrent cases of 
ARF in the NT in 2005-2010. Of these cases, 311 (98%) were 
Indigenous people. Recurrent cases made up 24% of all cases. 
Almost two-thirds (58%) of the Indigenous notifications were 
for children aged 5-14 years. 
•	 The rates for ARF were highest for Indigenous females in the 
5-14 years age group. Indigenous females accounted for more 
notifications for ARF than Indigenous males among those 
aged 5 or over.
Rheumatic heart disease
•	 In 2010, in the NT, there were 1,479 cases of RHD on the 
register. Almost all cases involved Indigenous people (1,379 
cases (93%)). After age-adjustment, rates for Indigenous 
people were 26 times higher than those for non-Indigenous 
people. 
Hospitalisations for ARF and RHD 
•	 In Australia in 2009-10, there were 2,666 hospitalisations 
for ARF and RHD, 0.6% of all CVD hospitalisations. Rates of 
hospitalisation among females were 1.3 times the rates of 
hospitalisations among males. The NT had the highest levels 
of hospitalisations (86 per 100,000) compared to Qld (15 per 
100,000) and WA (12 per 100,000). 
•	 During 2008-10, there were 702 hospitalisations in Australia for 
ARF and RHD for Indigenous people (4% of total hospitalisations 
for ARF and RHD). After age-adjustment, hospitalisation rates 
for ARF and RHD were 6.8 times higher for Indigenous people 
than for their non-Indigenous counterparts.
Deaths from ARF and RHD 
•	 In Australia in 2007-2009, there were 12 deaths recorded with 
the underlying cause of ARF, but no information was recorded 
about the Indigenous status of these deaths. During 2004-
2007, when Indigenous status was recorded), there were 13 
deaths recorded in NSW, Qld, WA, SA and NT; less than one-
third of these deaths recognised as being of an Indigenous 
person.
•	 In Australia in 2007-2009, there were 897 deaths with RHD 
as the underlying cause, 0.6% of all CVD deaths, and 0.2% of 
all deaths. Females had higher rates of deaths from RHD with 
1.5 times as many deaths than males. This is consistent with 
the higher levels of RHD and hospitalisation of RHD among 
females. 
•	 During 2006-2010, RHD was the cause of 90 Indigenous deaths 
at a level 4.7 times higher than that of non-Indigenous people. 
More than two-thirds or 61 of these deaths were of Indigenous 
females. 
Management
•	 Indigenous people do not receive the same level of primary 
prevention and management, emergency and acute care, 
rehabilitation, ongoing management, and secondary 
prevention care for cardiovascular disease (CVD) as do non-
Indigenous people.
•	 Many Indigenous people with a past history of ARF or 
RHD do not receive the recommended levels of penicillin 
prophylaxis. In 2002-2006, only 18% of eligible people in far 
north Queensland and the Kimberley region of WA received 
80% or more of their recommended doses in the preceding 
12 months; the low levels of prophylaxis are reflected in the 
proportion of ARF notifications classified as recurrences – 27% 
of cases for the Top End of the NT and 30% for central Australia. 
•	 An audit of control programs in far north Queensland and 
the Kimberley region of WA reported that only 20% of RHD 
patients had been prescribed an anticoagulant, 55% had 
been reviewed by a specialist in line with local management 
guidelines, 61% had had a timely echocardiogram, and 22% 
had undergone valve surgery.
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with antibiotics [13, 17]. Rates among the Indigenous population 
have not decreased to the same proportion as that among other 
Australians, with rates of ARF for Indigenous people in the Top 
End of the NT among the highest in the world. The World Heart 
Federation (WHF), which has recognised the disease as afflicting 
marginalised communities, has recently set a strategic goal to 
reduce worldwide deaths from the disease among those aged 25 
years by 25% by 2025 [18].
Socioeconomic factors, including living conditions (such as poor 
hygiene, inadequate clean water and sewerage, and overcrowding) 
and inaccessible health services, are linked to cases of ARF [8-10, 
13]. The relatively poor living conditions of many Indigenous 
people, particularly those living in remote areas, contributes to the 
high levels of ARF among Indigenous people. 
There is a correlation between cases of ARF/RHD and living 
conditions [8, 9, 11], but these analyses do not address possible 
considerations of heredity or genetic factors. Some research 
debates this correlation and concludes that the link between ARF/
RHD and living conditions is not significant, and that other factors 
need to be considered [12, 19].
Diagnosis 
There is currently no simple way of testing for ARF (such as by a 
blood test), and there is no definitive single symptom or sign of the 
disease. The disease is diagnosed using a set of criteria, comprising 
a combination of major and minor symptoms, following a group A 
streptococcal (GAS) infection (cases where there is no evidence of 
a previous GAS infection can only be considered probable cases of 
ARF) (see below guidelines) [20-23].
GAS infections can often cause pharyngitis. Prompt diagnosis and 
treatment of pharyngitis with antibiotics, is essential to prevent the 
development of ARF [23]. Diagnosis follows a positive throat swab 
culture for Streptococcus pyogenes.   
Guidelines
Guidelines for the diagnosis of ARF, first established in 1944, are 
referred to as the Jones criteria [20-22]. The criteria, which have 
been modified on several occasions (including 1956, 1965, 1984 
and 1992) in response to changes in disease characteristics, provide 
clearer definitions that assist in the assessment of borderline 
cases [20-22]. With each modification, the guidelines became 
more specific but less sensitive; in some cases they became less 
appropriate for use in populations with a high incidence (such as 
among Indigenous Australians).
Introduction 
In Australia, acute rheumatic fever (ARF) and rheumatic 
heart disease (RHD) continue to affect Indigenous2 
people disproportionally and represent the greatest disparity 
in cardiovascular health conditions between Indigenous and 
non-Indigenous people [5-10]. ARF remains almost exclusively 
experienced by Indigenous people in Australia today [1]. 
Indigenous children and young adults in Australia are the most 
affected by this disease, with rates being among the highest in the 
world [1, 8, 9, 11].
This review focuses on the burden of ARF/RHD for Indigenous 
people in Australia. It addresses overall prevalence, hospitalisation 
and mortality, and the factors contributing to this burden. This 
review also provides detailed information about the disease, 
its historical context, diagnosis, and guidelines. The review also 
considers: factors contributing to ARF/RHD; prevention and 
rehabilitation, and policies and strategies.
Acute rheumatic fever and 
rheumatic heart disease
ARF is an inflammatory disease that can cause damage to the 
heart muscle, valves and lining; it can also affect connective tissues 
in the brain and skeletal system [10]. ARF is commonly caused 
by an untreated bacterial throat infection, particularly group 
A streptococcus [8, 9, 11, 12]; more recently, there is growing 
debate about the causative role of streptococcal skin sores [8-14]. 
Research in the Top End of the Northern Territory (NT) found that 
of all Indigenous people with ARF who had throat swabs, 4% were 
positive for group A streptococcus, thus highlighting the possibility 
that the cause might be from another type of streptococcus in skin 
sores [13, 15]. Long-term damage of the heart valves and heart 
muscle following cases of ARF leads to RHD.
History and socioeconomic context
Worldwide, reported cases of ARF and RHD have decreased 
markedly in developed countries over the past century. During the 
period 1952 to 1978, notifications of ARF in Australia decreased 
from 6.4 per 100,000 to 0.3 per 100,000 [16]. New cases among the 
Australian population are now rare [13]; this has been attributed 
most commonly to improved living conditions and treatment 
2 The term Indigenous here refers to the two Indigenous population 
groups of Australia, Australian Aboriginal people and Torres Strait 
Islanders. 
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The World Health Organization (WHO) published guidelines in 
2004 [23]; the Australian guidelines were developed in 2005 [1, 24]. 
Guidelines for the diagnosis and management of RHD (including 
ARF) in Australia were based on a review by the National Heart 
Foundation of Australia and the Cardiac Society of Australia and 
New Zealand, and informed by the National Health and Medical 
Research Council [24]. The 2nd edition of these guidelines was 
released in 2012 [24].
The Australian guidelines, which contain criteria for use with high-
risk and low-risk populations, also include slightly different criteria 
for primary and recurrent episodes [1]. They were developed 
in response to concerns that the established criteria may not be 
sensitive enough for use with high incidence populations, such as 
Indigenous Australians. For initial episodes of ARF, the Australian 
guidelines support a definite diagnosis if two major or one major 
and two minor manifestations are present as well as evidence of an 
earlier GAS infection (without evidence of a previous GAS infection 
only a probable ARF diagnosis can be made). For recurrent 
cases of ARF the criteria provide for the inclusion of three minor 
manifestations as another alternative. 
Extent of acute rheumatic fever 
and rheumatic heart disease 
Incidence and prevalence 
Acute rheumatic fever
Box 1: Manifestations of ARF
For high-risk groups, major manifestations are inclusive of carditis 
(including sub-clinical evidence of rheumatic valvular disease 
on echocardiogram), polyarthritis or aseptic monoarthritis or 
polyarthralgia, chorea, erythema marginatum, and subcutaneous 
nodules [1]. Minor manifestations for high-risk groups include fever, 
erythrocyte sedimentation rate (ESR) greater than or equal to 30mm/h 
or C-reactive protein (CRP) level greater than or equal to 30mg/L, and 
prolonged PR interval on electrocardiogram (ECG). For suspected cases 
of ARF, the Australian guidelines recommend further investigations, 
including biochemical testing, blood culture, electrocardiogram, chest 
x-ray, throat swab, and streptococcal serology.
Box 2: Sources of information about ARF and RHD in Australia
Notifications of ARF began in the Northern Territory (NT) in 1994, 
followed by Queensland (Qld) in 1999, and Western Australia (WA) 
in 2007. ARF is currently not a notifiable disease in any other state or 
territory [25].
Information on cases of ARF and RHD reported in this review is mainly 
derived from registers in the Top End of the NT and central Australia3 
[9, 10, 24, 26]. These registers have been in effect since 1997 and 2000 
respectively and have now amalgamated to a state-wide program (2007)
[25]. Similar programs have been set up more recently in Far North Qld 
(2006) and WA (2009). The programs gather information about existing, 
past, new and recurrent cases of ARF, and RHD [10, 26]. The programs 
seek to facilitate improved follow-up for patients (including reviews), 
and to monitor the adherence to treatment regimens, such as primary 
and secondary prophylaxis [11]. 
3 Including parts of the NT and comprising neighbouring parts of SA 
and WA.
N o r t h e r n  T e r r i t o r y
In 2007-2010, there were 221 notifications of new and recurrent 
cases of ARF in the NT (Table 1) [27]. There were more cases 
recorded in the Top End, 160 cases, than in central Australia, 61 
cases [27]. Almost two-thirds (61%) of the Indigenous notifications 
were for children aged 5-14 years, with a rate of 2.3 cases per 1,000 
population. The rates for ARF were highest for Indigenous females 
in the 5-14 years age group (2.8 cases per 1,000) (Table 1) [27]. 
Indigenous females accounted for 139 (63%) of the notifications 
for ARF and Indigenous males for 82 notifications (37%). 
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years accounted for 131 (65%) of all notifications. More than one-
quarter (27%) of notifications were recurrences. The overall annual 
incidence rate was 0.6 notifications per 1,000 population; the rate 
for children aged 5-14 years was 1.6 per 1,000. The total numbers 
of notifications and the annual incidence rates increased between 
1999-2004 and 2004-2009, both overall and for children aged 5-14 
years
Table 2. Notifications of acute rheumatic fever among Indigenous 
people, by sex and selected age groups, north Qld, 1999-2004 
and 2004-2009
1999-2004 2004-2009
Total nofications 144 203
5-14 years (% total cases) 93 (65%) 131 (65%)
Annual incidence 0.5 0.6
Annual incidence (5-14 years) 1.2 1.6
Median age (years) 12.0 12.6
Female (% total persons) 67 (50%) 111 (57%)
Recurrences (% total cases) 33 (23%) 54 (27%)
Source: Hanna J, Clark M, 2010 [28]
Notes:  1 Annual incidence is per 1,000 population 
 2  Annual incidence (5-14 years) is per 1,000 children
 3 Time periods are mid 1999-mid 2004 and mid 2004-mid 2009 
W e s t e r n  A u s t r a l i a
In 2010-2011, there were 21 notifications of new and recurrent cases 
of ARF in WA [25]. All of these cases were of Indigenous people. 
Almost three-fifths (57%) of the notifications were for children 
aged 5-14 years. The levels of ARF were highest for Indigenous 
males in the 5-14 years age group. Indigenous males accounted for 
more notifications for ARF than females among all age groups.
An earlier analysis of ARF in the Kimberley region of WA found 
that there were 96 notifications of new and recurrent cases in 
1988-1992. All except one of the 81 people responsible for these 
notifications were Indigenous (Table 3) [29]. Over one-half (52%) 
or 42 of these were Indigenous females; Indigenous children 
aged 5-14 years accounted for 52% (50) of the total notifications. 
Recurrent cases made up 38% of the total notifications. The annual 
incidence rate for Indigenous people was 2.4 per 1,000. The rate for 
Indigenous children aged 5-14 years was 3.8 per 1,000.
Table 1. Notifications of acute rheumatic fever among Indigenous 
people, by sex and selected age groups, Northern Territory, 
2007-2010 
Sex Age groups All ages Rate 
ratio5-14 15-24 25-34
Males
Number 54 21 3 82 70.1
Rate 1.8 0.8 0.1 0.7
Females 
Number 81 32 14 130 74.6
Rate 2.8 1.3 0.6 1.1
Persons
Number 135 53 17 221 75.0
Rate 2.3 1.0 0.4 0.9
Source: Australian Institute of Health and Welfare, 2013 [27]
Notes:   1 Rates are per 1,000
  2 Age-specific figures calculated using the average number of registrations 
for 2007-2010 divided by the 2006 estimated resident Indigenous Australian 
population for the Top End, NT and central Australia 
  3 All ages includes 0-4 years and people aged 36 years or older
  4 Rate ratio is the Indigenous rate divided by the non-Indigenous rate.
Overall, Indigenous people experience levels of ARF more than 
75 times those of non-Indigenous people [27]. In 2007-2010, the 
Indigenous:non-Indigenous rate ratio for ARF was highest among 
females living in the Top End (78); the lowest statistically significant 
difference was found among females living in central Australia (54) 
[27]. 
Annual notification rates remained steady until 1999, and then 
fluctuated over the first decade of this century; rates in 2010 
were similar to those in 1996 (25 and 26 notifications per 100,000, 
respectively) [27].   
Q u e e n s l a n d
In 2009-2011, there were 178 notifications of new and recurrent 
cases of ARF in Qld [25]. Of these cases, 160 or 90% were Indigenous 
people. Recurrent cases made up 10% of all cases. Almost two-
thirds (60%) of the Indigenous notifications were for children aged 
5-14 years. Proportions of notifications were similar among females 
and males across all age groups (49% and 51% respectively). In the 
period 1999-2011, there were 502 cases of ARF in Qld, [25]. Average 
annual rates were much lower in Qld than in the NT (1 and 26 
notifications per 100,000 respectively). 
The more detailed information available for 2004-2009 reveals 
that the proportion of new and recurrent cases of ARF in the north 
Qld Indigenous population was higher for females than for males 
(females accounted for 111 (57%) of the 194 people responsible for 
203 cases notified in 2004-2009) (Table 2) [28]. Children aged 5-14 
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Table 4. Numbers and prevalence (%) of rheumatic heart disease among Indigenous people, and Indigenous:non-Indigenous ratios, by sex and age group, 
NT, 2010
Sex Age groups All ages
0-14 15-24 25-34 35-44 45-54 55-64 65+
Males
Number 53 121 108 92 62 26 13 475
Prevalence 4.6 19.0 21.5 22.6 23.9 21.3 18.5 17.8
Ratio ......... 100.1 139.9 76.4 32.7 47.6 5.9 28.2
Females
Number 68 184 215 198 137 67 35 904
Prevalence 6.2 29.3 39.8 46.1 47.1 43.6 30.3 32.6
Ratio ......... 137.5 123.1 79.5 42.9 14.3 5.2 24.4
Persons
Number 121 305 323 290 199 93 48 1379
Prevalence 5.4 24.1 31.0 34.6 36.2 33.7 25.8 25.7
Ratio ......... 120.1 131.1 80.6 40.0 21.8 6.0 27.3
Source: Australian Institute of Health and Welfare, 2013 [27]
Notes: 1  The prevalences for ‘All ages’ have been standardised
 2 Age-specific figures were calculated using the 2006 estimated resident Indigenous Australian population for the NT
 3 Ratio is the Indigenous prevalence divided by the non-Indigenous prevalence.
Table 3. Notifications of acute rheumatic fever among Indigenous 
people, by sex and selected age groups, Kimberley region of 
WA, 1988-1992
1988-1992
Total nofications 96
5-14 years (% total cases) 50 (52%)
Annual incidence 2.4
Annual incidence (5-14 years) 3.8
Median age (years) 13.3
Female (% total persons) 42 (52%)
Recurrences (% total cases) 37 (38%)
Source: Richmond P, Harris L,1998 [29]
Notes:  1 Annual incidence is per 1,000 population 
Rheumatic heart disease
N o r t h e r n  T e r r i t o r y
In line with the much higher notification rates of ARF, Indigenous 
people experience far higher levels of RHD than do non-Indigenous 
people [10]. In 2010, there were 1,479 cases of RHD on the register 
in the NT [25, 27]. Almost all cases involved Indigenous people 
(1,379 cases or 93%). After adjusting for the different population 
age structures, the prevalence among Indigenous people was 26 
times higher than that among non-Indigenous people (
Table 4) [27]. The prevalence among Indigenous people was high 
across all age groups particularly the 35-64 year age groups. For 
non-Indigenous people, the prevalence was the highest among 
those aged 65 years or older [25]. The greatest disparities between 
Indigenous people and non-Indigenous people were in the under 
35 year age groups.
Overall, the age-standardised figures were 18 for Indigenous 
males and 33 for Indigenous females (Table 5)[27]. Around 
one-third of all cases were Indigenous males and two-thirds 
Indigenous females. There was substantial disparity between 
Indigenous people and non-Indigenous people with the overall 
age-standardised rate ratios, 28 for males and 24 for females [26]. 
The greatest differences were seen among the 15-24 and 25-34 
years age groups with rates ratios 137 and 140 respectively4.
4 The ratio for the 0-14 group was not available, but, given the high 
prevalence in this age group, the disparity is likely to be high.
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In the Top End of NT and central Australia, there were 1,379 cases 
of RHD on the register in 2010; there were nearly three times as 
many cases recorded in the Top End (1,154) than in central Australia 
(325) [10, 27]. Almost all cases involved Indigenous people: 93% in 
the Top End and 94% in central Australia. Registered cases of RHD 
were 36 times higher for Indigenous males and 28 times higher 
for Indigenous females in the Top End of the NT than for their 
non-Indigenous counterparts (Table 5)[27]. In central Australia, 
registered cases were 13 times higher for Indigenous males and 17 
times higher Indigenous females than those for non-Indigenous 
males and females. The prevalence of RHD was highest among 
Indigenous females, 3.7% in the Top End of the NT (Table 5)[27]. 
Table 5. Prevalence (%) of rheumatic heart disease by Indigenous status 
and sex, Top End NT and central Australia, 2010
Area Indigenous status Ratio
Indigenous Non-Indigenous
Top End, NT 
Males 2.1 0.1 35.6
Females 3.7 0.1 27.7
Persons 2.9 0.1 32.4
Central Australia
Males 1.2 0.1 12.8
Females 2.4 0.1 17.4
Persons 1.8 0.1 16.3
Northern Territory
Males 1.8 0.1 28.2
Females 3.3 0.1 24.4
Persons 2.6 0.1 27.3
Source: Australian Institute of Health and Welfare, 2013 [27]
Notes: 1 Figures are directly age-standardised using the 2001 Australian standard 
population
 2 Rate ratio is Indigenous:non-Indigenous. All ratios are significant at the 
p<0.05 level
Q u e e n s l a n d
In 2012, there were 939 cases of RHD recorded in Qld. [25]. Almost all 
cases involved Indigenous people (845 cases or 90%). Almost two-
thirds (63%) of recorded cases were among females, particularly 
in the over 25 years age groups (66%). Among males, the highest 
levels of recorded cases of RHD were found among those aged less 
than 25 years (55%).
W e s t e r n  A u s t r a l i a
In 2011, in WA, there were 158 cases of RHD recorded [25]. All cases 
involved Indigenous people. Almost two-thirds (61%) of recorded 
cases were of Indigenous females. The highest level was recorded 
for the people aged less than 25 years (42%), followed by the 25-44 
year age groups (36%), and the 45years and over age groups (22%). 
Hospitalisation
In the two-year period July 2008 to June 2010, , ARF and RHD 
were responsible for 718 admissions to hospital of Indigenous 
people living in in NSW, Vic, WA, SA and the NT (Table 6) [26, 27]. 
The hospitalisation rate of Indigenous people for ARF and RHD 
was almost seven times higher than that for other Australians. 
The hospitalisation rate for Indigenous females (0.9 per 1,000) was 
higher than that for Indigenous males (0.4 per 1,000). Indigenous 
females were hospitalised for ARF and RHD at a level eight times 
that of other Australian females and Indigenous males five times 
the level of other Australian males. ARF and RHD accounted for 
0.6% of all CVD hospitalisations; levels were highest in the NT (86 
per 100,000) compared with Qld (15 per 100,000) and WA (12 per 
100,000) [25]. 
Table 6. Hospitalisations of Indigenous people for acute rheumatic fever 
and rheumatic heart disease, by sex, NSW, Vic, Qld, WA, SA and 
NT, July 2006 to June 2008 and July 2008 to June 2010
Sex 2006-08 2008-10
Male
Number 274 249
Rate 0.5 0.4
Rate ratio 5.3 4.8
Female 
Number 428 469
Rate 0.9 0.9
Rate ratio 8.2 8.3
Persons 
Number 702 718
Rate 0.7 0.7
Rate ratio 6.9 6.8
Source: Australian Institute of Health and Welfare, 2011, 2013 [26, 27]
Notes: 1  Rates are per 1,000
 2 Figures are directly age-standardised using the 2001 Australian standard 
population 
 3 Rate ratio is the Indigenous rate divided by the non-Indigenous rate.
Hospital procedures 
Indigenous people are more likely to be hospitalised for ARF and 
RHD than are non-Indigenous people, and less likely (around 40%) 
to undergo a procedure once admitted [25]. Between 2007-08 and 
2009-10, there were 675 hospitalisations of Indigenous people 
in Australia for ARF and RHD. Rates for hospitalisation among 
Indigenous people were 5.4 times as high as non-Indigenous 
people, however Indigenous people were less likely to receive 
a heart valve procedure 28% compared with 49% among non-
Indigenous people.
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Hospital expenditure
Hospital expenditure for all admitted Indigenous people during 
2008-09 was $1470.5 million [25]. ARF/RHD made up 0.4% ($5.9 
million) of the total amount of expenditure for Indigenous people, 
and per person this figure was 4.3 times as high as that of non-
Indigenous people ($11 per person compared with $2 per person 
respectively).  
Avoidable deaths
There were 87 avoidable deaths of Indigenous people from RHD 
during the period 2006-2010 (Table 7)[27]. After age-adjustment, 
the rate for avoidable deaths from RHD was more than 13 times 
higher for Indigenous people than for non-Indigenous people.
Table 7. Avoidable mortality from rheumatic heart disease, by 
Indigenous status, NSW, Qld, WA, SA and NT, 2006-2010
Indigenous Non-Indigenous 
Number 87 290
Percent 1.3 0.3
Per 100,000 5.2 0.4
Rate ratio 13.3 ............
Source: Australian Institute of Health and Welfare, 2013 [27]
Notes: 1 Figures are directly age-standardised using the 2001 Australian standard 
population 
 2 Rate ratio is the Indigenous rate divided by the non-Indigenous rate.
 3 Percent is of all avoidable causes of deaths
Mortality
ARF was the underlying cause of 12 deaths in Australia during 
2007-2009, but no information was recorded about the Indigenous 
status of these deaths [25]. During 2004-2007, there were 13 deaths 
recorded in NSW, Qld, WA, SA and NT; less than one-third of these 
deaths were identified as being of Indigenous people.  
During 2006-2010 RHD was the cause of 90 Indigenous deaths at 
a rate 4.7 times higher than that of non-Indigenous people (Table 
8) [26, 27]. More than two-thirds (61) of these deaths were of 
Indigenous females. Recorded deaths among Indigenous females 
were 7.7 per 100,000 and Indigenous males were 3.3 per 100,000. 
Indigenous females suffered a greater disparity than Indigenous 
males with their non-Indigenous counterparts: rate ratios of 5.3 
and 3.5 respectively. 
The actual numbers of deaths from RHD have decreased between 
the periods 2002-2006 and 2006-2010, the rates and rate ratios 
have also decreased for both Indigenous males and females [26]. 
Deaths per 100,000 for Indigenous males decreased from 6.2 to 3.3 
during this time, and for Indigenous females decreased from 16.0 
to 7.7. The rate ratios also decreased from 6.1 to 3.5 for Indigenous 
males and 10.9 to 5.3 for Indigenous females. 
Table 8. Deaths of Indigenous people from rheumatic heart disease, by 
sex, NSW, Qld, WA, SA and NT, 2002-2006 and 2006-2010
Sex 2002-2006 2006-2010
Male
Number 30 29
Rate 6.2 3.3
Rate ratio 6.1 3.5
Female 
Number 67 61
Rate 16.0 7.7
Rate ratio 10.9 5.3
Persons
Number 97 90
Rate 11.5 5.7
Rate ratio 9.0 4.7
Source: Australian Institute of Health and Welfare, 2011,2013 [26, 27]
Notes: 1 Rates are per 100,000
 2 Data recorded for the period 2002-2006 does not include NSW data due to 
inadequate levels of Indigenous identification at that time.  
 3 Figures are directly age-standardised using the 2001 Australian standard 
population
 4 Rate ratio is Indigenous:non-Indigenous. All ratios are significant at the 
p<0.05 level
Age-specific death rates
Over one-half of deaths of Indigenous people from RHD occurred 
in the 25-54 years age group; the highest number of deaths was 
for people aged 25-34 years with 22 deaths recorded (Table 9)[27]. 
Deaths from RHD among people aged 15-24 years accounted for 
27% of all CVD deaths for that age group. 
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(the causative agent for ARF), and reduce the need for early 
detection and treatment with antibiotics to prevent ARF [24, 34]. 
There is also a great need for health care providers to concentrate 
on meeting the needs of Indigenous people through better 
prevention, diagnosis, service delivery and access to care [35, 36].
Primordial prevention requires broad political commitment to 
addressing the social, economic and environmental inequities 
experienced by Indigenous people [1, 24, 35]. Improvements in 
the interrelated areas of housing, education and employment are 
required to address chronic disease, rather than concentrating 
mainly on health service delivery [37]. Even after allowing for the 
effects of behavioural and biomedical risk factors (such as smoking, 
physical inactivity and obesity); socioeconomic variables remain 
independently associated with the risk of death from CVD [38]. 
Limitations in the delivery of holistic care seem to be due to a lack 
of structure between services of the commonwealth, and state and 
territory governments in this area. Many areas affecting health, 
including education, employment, social services, and transport 
are not greatly influenced by the health sector, and therefore 
national health policies for Indigenous people require much 
greater integration [9, 13, 24, 39, 40].
Primary prevention
Primary prevention of ARF and RHD starts with the prevention, 
prompt diagnosis and treatment of group A streptococcus upper 
respiratory tract infection pharyngitis/tonsillitis with antibiotics 
(referred to as primary prophylaxis) [23, 24]. This can prevent 
an initial attack of ARF from developing, and can help to control 
the spread of infection. Group A streptococcal pharyngitis can 
be diagnosed with throat sample cultures taken from swabs 
of suspected cases. Effective oral antibiotic treatment, such as 
penicillin, aims to eradicate group A streptococcal in the upper 
respiratory tract and it can prevent the development of ARF if the 
treatment commences within 9 days of the initial symptoms.  
There is considerable potential for reduction in the levels of ARF 
and RHD among Indigenous people, but there must be committed 
application of the knowledge currently available [1, 24]. As well as 
From 1979-1996, in Australia, deaths rates for RHD reduced by 
more than 50% from 2.0 to 0.9 per 100,000 for males and 3.1 to 
1.1 per 100,000 for females [25]. Following this was an increase of 
0.8 deaths per 100,000 up to1997 before figures stabilised in 1998. 
During the 31 year period, up to 2009, deaths rates have continued 
to be higher for females.
Prevention and management 
Prevention and treatment programs for ARF and RHD in Australia 
have increased in recent years, and their focus is moving towards a 
coordinated national approach [8, 9, 11, 12, 31, 32]. The Rheumatic 
fever strategy provides a coordinated program for the prevention 
and treatment of ARF and RHD among Indigenous people, 
particularly children [31, 32]. Prevention of ARF and RHD occurs 
at a primordial, primary, secondary and tertiary level, each one 
targeting different stages of the disease, from the prevention of 
new cases of ARF to the reduction of disability and premature 
death from RHD. 
The prevention and treatment of ARF and RHD involves two 
complementary parts: (1) the surveillance, identification and 
registration of new and recurrent cases, and education for health 
professionals [24, 31, 33]; and (2) working with the family and 
local community of those with ARF/RHD, through measures such 
as health promotion, education, and supporting adherence to 
primary and secondary prophylaxis [8, 9, 11, 12, 24, 31, 33].
Further prevention measures can include training of health care 
providers and the involvement of schools and wider communities 
to work together and play a role in the prevention and control of 
ARF and RHD [23]. 
Primordial prevention
ARF and RHD are preventable causes of morbidity and mortality 
among Indigenous people; and organised primary health care 
is essential for their control [24]. Primordial prevention requires 
improvements in socioeconomic conditions and housing, which 
would lower the carriage and transmission of group A streptococci 
Table 9. Age-specific deaths from rheumatic heart disease among Indigenous people, by age group, NSW, Qld, WA, SA and NT, 2004-2008
Under 1 1-4 0-4 5-14 15-24 25-34 35-44 45-54 55-64 65-74 75+ All ages
Rheumatic  0 4 4 ......... 10 22 18 15 12 5 ......... 90
heart disease 0% 50% 16% ......... 27% 16% 5% 3% 2% 1% ......... 3%
Total circulatory disease 16 8 24 6 36 135 388 559 546 527 703 2925
 Source: Australian Institute of Health and Welfare, 2013 [27]
Notes: 1 Percent (%) is the percentage of all circulatory age specific deaths 
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Rheumatic fever strategy 
The Rheumatic fever strategy aims to address ARF and RHD among 
Indigenous people, particularly children. It provides a coordinated 
program including: prevention and treatment; funding for state-
based registers and control programs in the NT, WA and Qld; and 
a national coordination unit, RHD Australia. The strategy builds 
on the Rheumatic heart disease control program, which was 
established in the Top End of the NT in 1997 and extended to 
include central Australia in 2000 (where it became fully operational 
in 2002) [24, 31, 32]. 
The keys outcomes of this strategy include improvements to 
clinical responses, and support for monitoring and treatment 
of ARF and RHD through the establishment of a national data 
collection system. These outcomes will be achieved by: conducting 
surveillance; identifying and registering new and recurrent cases; 
providing education and training for health care providers; 
improving clinical care and follow-up; providing education and 
health promotion to clients, families and the community; and 
supporting the uptake of and adherence to secondary prophylaxis 
[24, 31, 33].
Management
The management of ARF and RHD involves both prevention of 
recurrent cases of ARF and the appropriate, timely medical and 
surgical management of those with RHD [24, 44].
ARF can be difficult to diagnose, but early diagnosis of ARF is 
essential to ensure that preventive measures can be implemented 
in a timely manner to lessen the risk of developing recurrent 
ARF and RHD [44]. Suspected cases of ARF should be referred to 
hospital as soon as possible after the onset of symptoms. The use of 
echocardiography to identify evidence of carditis has recently been 
included as a criterion in the national guidelines; suspected ARF 
cases should now have an echocardiogram shortly after hospital 
admission [44-46]. Other investigations for suspected ARF can 
include: white blood cell count; erythrocyte sedimentation rate; 
C-reactive protein; blood cultures; electrocardiogram; chest x-ray; 
throat swab; and anti-streptococcal serology. The importance and 
urgency of an accurate diagnosis and prompt treatment of ARF 
can be overlooked by medical staff, particularly in areas where 
occurrences of ARF are rare.   
The proportion of ARF notifications classified as recurrences is an 
important indicator of the effectiveness of ARF control programs 
[47]. The proportion of recurrences has probably declined in recent 
years, but still comprised 27% of cases for the Top End of the NT and 
action addressing the various behavioural risk factors, attention 
also needs to be directed to the adverse social, economic, and 
environmental conditions of many Indigenous people.
Secondary prevention
Secondary prevention measures are used with individuals who 
have established RHD, to help prevent further progression of the 
disease [24]. Secondary prevention is through treatment with 
antibiotic injections; this is referred to as secondary prophylaxis. 
It is important in preventing recurrences of group A streptococcal 
infections and recurrent cases of ARF, which can further damage 
the heart and increase the risks of establishing RHD [23, 24]. In order 
to be effective, a high level of prophylaxis must be achieved with 
regular long-term treatment with penicillin. Four-weekly doses of 
antibiotics are the treatment of choice. In patients considered to 
be at high risk, 3-weekly administration may be appropriate. The 
benefits of a shorter duration between each course of medication 
are offset by the difficulties of achieving good adherence to the 
regimen. The appropriate duration of secondary prophylaxis is 
determined by age, time since the last episode of ARF, potential 
harm from recurrent disease, presence and severity of RHD, number 
of previous attacks, family history, socioeconomic status, and risk of 
streptococcal infection in the area [23, 24, 41]. Treatment is usually 
continued for approximately 10 years or until the age of 21 years, 
whichever is longer [8, 9, 11, 12, 24]. 
In 2009, nearly one-quarter (23%) of Indigenous people registered 
with the ARF/RHD program adhered to secondary prophylaxis at a 
level more than 80% of their required doses [26]. Two-fifths (41%) 
met 50-80% of required doses, and one-third (36%) met less than 
50% of required doses. Adherence was greatest in the Top End 
of the NT with one-quarter (25%) meeting over 80% of required 
doses, compared with almost one-fifth (17%) in central Australia.  
Tertiary prevention
Tertiary prevention includes measures used with individuals who 
have established RHD to help reduce symptoms and disability, 
as well as prevent premature deaths [24]. For Indigenous people 
with established RHD, access to cardiac surgery and other medical 
treatment may be important. This form of prevention is considered 
to be the least cost effective of all the prevention initiatives for this 
disease [42, 43].
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The progression of valve damage is much more rapid among 
Indigenous patients with RHD than among their non-Indigenous 
counterparts: the mean age for 45 Indigenous patients from the NT 
who had undergone mitral valve repair procedures at the Flinders 
Medical Centre was 23 years [51]. Around 45% of the Indigenous 
patients and 4% of non-Indigenous patients were less than 25 years. 
Despite their youth, many of the Indigenous patients had major 
valve destruction as well as substantial comorbidity. Short-term 
results were similar for Indigenous and non-Indigenous patients, 
but long-term outcomes were worse for Indigenous patients than 
for their non-Indigenous counterparts. 
Concluding comments
The extent of ARF and RHD is still very high among some 
Indigenous people in Australia; in comparison, the conditions are 
very uncommon among non-Indigenous people. Hospitalisations 
and deaths from ARF and RHD continue to burden Indigenous 
people at a rate around seven times the rate for other Australians. 
Being linked to poverty, poor living conditions and limited access to 
health services, ARF and RHD are largely preventable, as evidenced 
by the very low levels among non-Indigenous Australians (and in 
other developed countries). 
The recently established national coordination strategies for 
the prevention and treatment of ARF and RHD emphasise the 
great importance of primary and secondary prophylaxis. Early 
diagnosis is essential to curb the risk of developing recurrent ARF 
and RHD. Secondary prophylaxis generally involves four-weekly 
administration of intramuscular benzathine penicillin, but the 
long-term adherence required can be problematic due to: mobility 
of patients; the pain of injection (particularly for young people); 
and levels of service provision. And, of course, improvements in 
the living conditions of Indigenous Australians – and their access 
to health services – are essential to prevent new cases of ARF and 
RHD and reduce the risks of disease progression.
30% for central Australia in 2002-2006 [10]. These levels confirm 
ongoing shortcomings with secondary prophylaxis programs, 
which are most effectively implemented very early in the natural 
history of RHD; with effective prophylaxis, many people with mild 
RHD may have no detectable disease 5 to 10 years later [24, 40]. The 
main shortcoming with current secondary prophylaxis programs is 
that many people with a past history of ARF or RHD do not receive 
the recommended levels of penicillin prophylaxis, optimally with 
intra-muscular benzathine penicillin G [24]: an audit of control 
programs in far north Queensland and the Kimberley region of WA 
found that only 18% of eligible people had received 80% or more 
of their doses in the preceding 12 months [48].
Adherence to secondary prophylaxis can be impacted by the 
availability and accessibility of health services, particularly in 
remote areas [44]. Studies conducted in the NT found that improved 
adherence occurred when: patients felt a sense of belonging 
to a health clinic; dedicated staff administered treatment; and 
active follow-up was made by clinic staff. Barriers impacting on 
the delivery of injections included: pain of injection (particularly 
for young people); high staff turnover; mobility of patients; size 
and complexity of the community and its health service; as well 
as a lack of supportive infrastructure. Potential strategies to 
improving the adherence to injections could include: increased 
use of Aboriginal Health Workers; regular contact with health 
clinics; recall and reminder systems; centralised co-ordination; 
promoting the importance of timely treatment through health 
education for staff, patients and families; support that extends 
beyond community boundaries [44, 49]. The various possible 
manifestations of RHD – damage to the heart valves and associated 
structures, cardiomyopathy, atrial fibrillation, systemic embolism, 
TIAs and strokes, and infective endocarditis [50] – require ongoing 
monitoring and appropriate medical and surgical management. 
For people with established RHD, best practice requires: secondary 
prevention; monitoring of anticoagulant therapy (for people with 
AF and/or mechanical prosthetic valves); access to oral healthcare; 
access to echocardiography; access to appropriate specialist(s); 
and access to cardiothoracic and interventional cardiology services 
[24]. 
There is no comprehensive information about how these 
requirements are being addressed, but an audit of control 
programs in far north Queensland and the Kimberley region of 
WA reported that only 20% of RHD patients had been prescribed 
an anticoagulant, 55% had been reviewed by a specialist in 
line with local management guidelines, 61% had had a timely 
echocardiogram, and 22% had undergone valve surgery [48]. 
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working to improve Indigenous health – its free on line 
yarning places enable people across the country to share 
information, knowledge and experience. The HealthInfoNet 
is funded mainly by the Australian Department of Health 
and Ageing. Its award-winning web resource (www.
healthinfonet.ecu.edu.au) is free and available to everyone.
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